

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	Not Yet Assigned
			Filing Date	Even Date Herewith
			First Named Inventor	Johan FROSEGARD
			Group Art Unit	1641
			Examiner Name	L. COOK
			Attorney Docket Number	FROSTEGARD=1D
Sheet	1	of	2	

[illegible][illegible]

Examiner Signature	<i>Risa L Cook</i>	Date Considered	12/7/05
-----------------------	--------------------	--------------------	---------

* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Not Yet Assigned
		Filing Date	Even Date Herewith
		First Named Inventor	Johan FROSTEGARD
		Group Art Unit	
		Examiner Name	
Sheet 2	of 2	Attorney Docket Number	FROSTEGARD=1D

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
LK	AB	BALDO et al, "A specific, sensitive, and high capacity immunoassay for PAF". 1991). 26(12):1136-1139.	
	AC	BARQUINERO, Jordi, et al "Antibodies Against Platelet-Activating Factor In Patients With Antiphospholipid Antibodies". Lupus, Vol. 3 (1994), pp. 55-58.	
	AD	FROSTEGARD et al, "Association of Serum Antibodies to Heat-Shock Protein 65 With Borderline Hypertension", HYPERTENSION, 29(1), pp. 40-44, 1997.	
	AE	FROSTEGARD et al, "Platelet-Activating Factor and Oxidized LDL Induce Immune Activation by a Common Mechanism", ARTERIOSCLEROSIS, 17(5), pp 963-968, 1997.	
	AF	HARRIS et al, "Evaluation of the Anti-Cardiolipin Antibody Test: Report of an International Workshop held 4 April 1986", Clin. Exp Immunol, 1987 Apr; 68(1):215-222.	
	AG	HIRASHIMA Y et al, "Platelet-activating factor (PAF) and the formation of chronic subdural haematoma. Measurement of plasma PAF levels and anti-PAF immunoglobulin titers". & ACTA Neurochir. (1995) 137(1-2):15-18. (Dialog Information Services, File 154, MEDLINE, Dialog accession no. 08672149, Medline accession no. 96350619)	
	AH	KARASAWA et al, "Radioimmunoassay for platelet activating factor". Lipids. (1991). 26(12):1126-1129.	
	AI	LEMNE et al, "Carotid Intima-Media Thickness and Plaque Borderline Hypertension" STROKE, 26(1); pp. 34-39; 1995	
LK	AJ	OSTERMANN et al, "The degradation of platelet activating factor in serum and its discriminative value in atherosclerotic patients." Thrombosis Research. (1998). 52:529-540.	

Examiner Signature	<i>Quana Cook</i>	Date Considered	12/7/05
--------------------	-------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



BN/SB/08A/B

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/814,125
Filing Date	April 1, 2004
First Named Inventor	Johan FROSTEGARD
Group Art Unit	1643 1641
Examiner Name	L. COOK
Attorney Docket Number	FROSTEGARD =1D

Sheet	1	of	1
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
LVC	AK	US-4,444,879	04-28-1984	FOSTER et al	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
LVC	AL	BOGGS, Will, "Chronic H. Pylori Infection Linked to Early Vascular Disease", Society for Vascular Surgery. [online], [retrieved July 5, 2005]. VascularWeb.org. Retrieved from Internet <URL: http://svs.vascularweb.org/_contribution_pages/medical_news_reuters/pag... > reprint of : J AM Coll Cardiol. (2005). 45:1219-1222.	
LVC	AM	KOH, Kian, et al, "T cell-mediated vascular dysfunction of human allografts results from IFN- γ dysregulation of NO synthase". The Journal of Clinical Investigation. (September 2004). 114(6):846-856.	

Examiner Signature	<i>Olivia L. Cook</i>	Date Considered	12/7/05
-----------------------	-----------------------	--------------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/814,125
Filing Date	April 1, 2004
First Named Inventor	Johan FROSTEGARD
Group Art Unit	1614 1641
Confirmation No.	8029
Attorney Docket Number	FROSTEGARD =1D

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner
Signature**

Gesa. & Cook

Date
Considered

12/7/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.